A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease

Nature Genetics

Volumn 37, Issue 5, 2005, Pages 526-531

  Giorgini, Flaviano ^a   Guidetti, Paolo ^b   Nguyen, QuangVu ^a   Bennett, Simone C ^a   Muchowski, Paul J ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; KYNURENINE 3 MONOOXYGENASE; NEUROPROTECTIVE AGENT; POLYGLUTAMINE; REACTIVE OXYGEN METABOLITE; RO 618048; TRYPTOPHAN; UNCLASSIFIED DRUG;

ARTICLE; CELL INCLUSION; DEGENERATIVE DISEASE; FUNGAL GENE; GENE DELETION; GENE MUTATION; GENETIC SCREENING; HUNTINGTON CHOREA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; YEAST;

AUTOPHAGY; HUMANS; HUNTINGTON DISEASE; KYNURENINE 3-MONOOXYGENASE; MICROGLIA; MIXED FUNCTION OXYGENASES; MUTATION; SACCHAROMYCES CEREVISIAE;

EID: 18144406846     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/ng1542     Document Type: Article

References (30)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983 (1993).
2. Scherzinger, E. et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558 (1997).
3. Willingham, S., Outeiro, T.F., DeVit, M.J., Lindquist, S.L. & Muchowski, P.J. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 302, 1769-1772 (2003).
4. Schwarcz, R. The kynurenine pathway of tryptophan degradation as a drug target. Curr. Opin. Pharmacol. 4, 12-17 (2004).
5. Merlin, A.B. et al. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J. Cell Biol. 157, 997-1004 (2002).
6. Muchowski, P.J., Ning, K., D'Souza-Schorey, C. & Fields, S. Requirement of an intact microtubule cytoskeleton for aggregation and inclusion body formation by a mutant huntingtin fragment. Proc. Natl. Acad. Sci. USA 99, 727-732 (2002).
7. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004).
8. Ravikumar, B., Duden, R. & Rubinsztein, D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11, 1107-1117 (2002).
9. Qin, Z.H. et al. Autophagy regulates the processing of amino terminal huntingtin fragments. Hum. Mol. Genet. 12, 3231-3244 (2003).
10. Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585-595 (2004).
11. Sugars, K.L. & Rubinsztein, D.C. Transcriptional abnormalities in Huntington disease. Trends Genet. 19, 233-238 (2003).
12. Steffan, J.S. et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413, 739-743 (2001).
13. Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl. Acad. Sci. USA 100, 2041-2046 (2003).
14. Ferrante, R.J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427 (2003).
15. Mallory, M.J. & Strich, R. Ume1p represses meiotic gene transcription in Saccharomyces cerevisiae through interaction with the histone deacetylase Rpd3p. J. Biol. Chem. 278, 44727-44734 (2003).
16. Michelitsch, M.D. & Weissman, J.S. A census of glutamine/asparagine- rich regions: implications for their conserved function and the prediction of novel prions. Proc. Natl. Acad. Sci. USA 97, 11910-11915 (2000).
17. Schwarcz, R., Whetsell, W.O. Jr. & Mangano, R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219, 316-318 (1983).
18. Guidetti, P., Luthi-Carter, R.E., Augood, S.J. & Schwarcz, R. Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol. Dis. 17, 455-461 (2004).
19. Guidetti, P. & Schwarcz, R. 3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum. Eur. J. Neurosci. 11, 3857-3863 (1999).
20. Guidetti, P., Reddy, P.H., Tagle, D.A. & Schwarcz, R. Early kynurenergic impairment in Huntington's disease and in a transgenic animal model. Neurosci. Lett. 283, 233-235 (2000).
21. Goda, K., Hamane, Y., Kishimoto, R. & Ogishi, Y. Radical scavenging properties of tryptophan metabolites. Estimation of their radical reactivity. Adv. Exp. Med. Biol. 467, 397-402 (1999).
22. Rover, S., Cesura, A.M., Huguenin, P., Kettler, R. & Szente, A. Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl) benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. J. Med. Chem. 40, 4378-4385 (1997).
23. Moroni, F., Cozzi, A., Peruginelli, F., Carpenedo, R. & Pellegrini-Giampietro, D.E. Neuroprotective effects of kynurenine-3-hydroxylase inhibitors in models of brain ischemia. Adv. Exp. Med. Biol. 467, 199-206 (1999).
24. Richter, A. & Hamann, M. The kynurenine 3-hydroxylase inhibitor Ro 61-8048 improves dystonia in a genetic model of paroxysmal dyskinesia. Eur. J. Pharmacol. 478, 47-52 (2003).
25. Schwarcz, R. & Pellicciari, R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J. Pharmacol. Exp. Ther. 303, 1-10 (2002).
26. Wyttenbach, A. et al. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum. Mol. Genet. 11, 1137-1151 (2002).
27. Perez-Severiano, F. et al. Increased formation of reactive oxygen species, but no changes in glutathione peroxidase activity, in striata of mice transgenic for the Huntington's disease mutation. Neurochem. Res. 29, 729-733 (2004).
28. Sapp, E. et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60, 161-172 (2001).
29. Ryu, J.K., Kim, S.U. & McLarnon, J.G. Blockade of quinolinic acid-induced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington's disease. Exp. Neurol. 187, 150-159(2004).
30. Zhang, X. et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc. Natl. Acad. Sci. USA 102, 892-897 (2005).